Baxter International BAX
Baxter International Inc. is a medical devices and supplies company that develops and markets products for renal, hospital, and clinical nutrition therapies. Baxter shows solid growth (revenue +5.30%, earnings +36.80%) and attractive valuation (forward P/E 11.48, PEG 0.33), but its high leverage (Net Debt/EBITDA 3.99) and negative ROE (-14.37%) weigh on its quality and financial health profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Baxter International Inc. is a medical devices and supplies company that develops and markets products for renal, hospital, and clinical nutrition therapies. Baxter shows solid growth (revenue +5.30%, earnings +36.80%) and attractive valuation (forward P/E 11.48, PEG 0.33), but its high leverage (Net Debt/EBITDA 3.99) and negative ROE (-14.37%) weigh on its quality and financial health profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.0 |
| Quality / Moat | 4.6 |
| Valuation | 5.0 |
| Growth | 7.1 |
| Dividend | 0.6 |
| Momentum | 6.9 |
| Risk & Context | 7.6 |
OVERALL SCORE: 5.3/10
Context and risks
Baxter has a very high Net Debt/EBITDA of 3.99. Although the Fed is leaning toward rate cuts, the rise in the 10-year Treasury to 5.17% makes refinancing its debt more expensive, a material risk to its financial health.
News considered in the analysis
- BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure — La mejora de la guía para 2026 es un hecho material que confirma la fortaleza del crecimiento de ingresos (5.30%) y beneficios (36.80%), aunque el mercado ya lo ha descontado parcialmente tras la publicación de resultados.
- Here's Why You Should Retain Baxter Stock in Your Portfolio for Now — Artículo de opinión de Zacks sin información nueva; es ruido.
- 2 Volatile Stocks for Long-Term Investors and 1 Facing Challenges — Listículo genérico sin datos específicos sobre Baxter; sin impacto.
- Is Baxter Stock Underperforming the Nasdaq? — Comparativa de rendimiento bursátil sin información fundamental nueva; ruido.
- Microsoft Leads S&P 500 Stocks Going Nowhere — Titular sobre Microsoft, sin relación con Baxter; irrelevante.
Verdict: Hold; growth and valuation offset balance sheet risk, but debt and unsustainable payout limit upside potential.
Main risk: High leverage (Net Debt/EBITDA 3.99) combined with a 307.69% payout makes the company vulnerable to tighter financing conditions or a growth slowdown.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →